Discrimination of different degrees of oral squamous cell carcinoma by means of Raman microspectroscopy and atomic force microscopy

Two cellular types characterized by different degree of oral squamous cell carcinoma can be discriminated by Raman microspectroscopy and Atomic Force Microscopy, according to the content of nucleic acids and proteins as well as the membrane stiffness.

Glycolytic potential and activity of adenosine monophosphate kinase (AMPK), glycogen phosphorylase (GP) and glycogen debranching enzyme (GDE) in steer carcasses with normal (<5.8) or high (>5.9) 24h pH determined in M. longissimus dorsi

Muscle glycogen concentration (MGC) and lactate (LA), activity of glycogen debranching enzyme (GDE), glycogen phosphorylase (GP) and adenosine monophosphate kinase (AMPK) were determined at 0.5h (T0) and 24h (T24) post-mortem in Longissimus dorsi samples from 38 steers that produced high pH (>5.9) and normal pH (<5.8) carcasses at 24h postmortem. MGC, LA and glycolytic potential were higher (P<0.05) in normal pH carcasses. GDE activity was similar (P>0.05) in both pH categories. GP activity increased between T0 and T24 only in normal pH carcasses. AMPK activity was four times higher in normal pH v/s high pH carcasses, without changing its activity over time. Results reinforce the idea that differences in postmortem glycogenolytic/glycolytic flow in L. dorsi of steers showing normal v/s high muscle pH at 24h, could be explained not only by the higher initial MGC in normal pH carcasses, but also by a high and sustained activity of AMPK and an increased GP activity at 24h postmortem.

Drivers of animal welfare policy in the Americas

Owing to its large size and ethnic, social, cultural and economic diversity, the Americas' production volume is set to make the region one of the world's leading providers of animal foodstuffs. Animal husbandry, transport and slaughter conditions vary from country to country in response to their differing climatic and geographic characteristics. This article examines the main drivers of animal welfare in the Americas, including the standards of the World Organisation for Animal Health (OIE), legislation, codes of practice and advances in education, training, research and development. It recognises the important roles played by all the various stakeholders in changing perceptions of animal welfare by raising public awareness and promoting communication and cooperation as drivers of overall change in the Americas. Regional and international organisations, public and private-sector bodies, academia and non-governmental organisations have launched a number of initiatives with encouraging results. In 2009, the OIE established the Chile-Uruguay Collaborating Centre for Animal Welfare Research, which is now the OIE Collaborating Centre for Animal Welfare and Livestock Production Systems and has recently incorporated Mexico. The Collaborating Centre works closely with official OIE Delegates and the Focal Points for Animal Welfare of national Veterinary Services. The OIE Regional Animal Welfare Strategy for the Americas was adopted in 2012, under the coordination of the OIE Regional Representation for the Americas, as a guide for developing future policies based on a regional approach. The way to achieve cultural change for improving animal welfare, operator safety and the sector's profitability is through training and knowledge transfer. The results demonstrate that the joint efforts of all institutions and the active role of the Collaborating Centre have been most effective, as have the continuing education programmes implemented by universities.

Validación de la Escala de Depresión de Edinburgh en mujeres que no están en el periodo postparto

.

Dental treatment in Angelman syndrome patients. 8 case reports

AIM

Angelman syndrome is a rare neurogenetic disorder resulting in delayed neuropsychological development, intellectual disability, speech impairment, movement or balance disorder and a behavioural uniqueness. It is caused by deletion of maternal chromosome 15q11-13. The syndrome has oral manifestations such as diastemas, tongue thrusting, sucking/swallowing disorder, mandibular prognathism, and wide mouth. The dental literature on the syndrome is scarce.

CASE REPORT

We report our approach to dental procedures in Angelman syndrome patients, and the relationship between the dental staff and the patient and his family. The purpose of this paper is to highlight the possibility of dental treatment in general anaesthesia, due to the lack of cooperation of some of these patients.

Polycystic Ovary-Like Abnormalities (PCO-L) in women with functional hypothalamic amenorrhea

CONTEXT

In the general population, about 30% of asymptomatic women have polycystic ovary-like abnormalities (PCO-L), i.e. polycystic ovarian morphology (PCOM) at ultrasound and/or increased anti-Müllerian hormone (AMH) serum level. PCOM has also been reported in 30-50% of women with functional hypothalamic amenorrhea (FHA).

OBJECTIVE

The aim of this study was to verify whether both PCOM and excessive AMH level indicate PCO-L in FHA and to elucidate its significance.

DESIGN

We conducted a retrospective analysis using a database and comparison with a control population.

SETTING

Subjects received ambulatory care in an academic hospital.

PATIENTS

Fifty-eight patients with FHA were compared to 217 control women with nonendocrine infertility and body mass index of less than 25 kg/m(2).

INTERVENTIONS

There were no interventions.

MAIN OUTCOME MEASURES

We measured serum testosterone, androstenedione, FSH, LH, AMH, and ovarian area values. The antral follicle count (AFC) was used as a binary variable (i.e. negative or positive) because of the evolution of its sensitivity over the time of this study. The ability of these variables (except AFC) to detect PCO-L in both populations was tested by cluster analysis.

RESULTS

One cluster (cluster 2) suggesting PCO-L was detected in the control population (n = 52; 24%), whereas two such clusters were observed in the FHA population (n = 22 and n = 6; 38 and 10%; clusters 2 and 3, respectively). Cluster 2 in FHA had similar features of PCO-L as cluster 2 in controls, with higher prevalence of positive AFC (70%) and PCOM (70%), higher values of ovarian area and higher serum AMH (P < 0.0001 for all), and testosterone levels (P < 0.01) than in cluster 1. Cluster 3 in FHA was peculiar, with frankly elevated AMH levels. In the whole population (controls + FHA), PCO-L was significantly associated with lower FSH values (P < 0.0001).

CONCLUSION

PCO-L in FHA is a frequent and usually incidental finding of unclear significance, as in controls. The association of PCO-L with hypothalamic amenorrhea should not lead to a mistaken diagnosis of PCOS.

Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study

BACKGROUND

To measure bone mineral density (BMD) reduction produced by letrozole as compared with tamoxifen and the benefit of the addition of zoledronic acid.

PATIENTS AND METHODS

A phase 3 trial comparing tamoxifen, letrozole or letrozole+zoledronic acid in patients with hormone receptor-positive early breast cancer was conducted; triptorelin was given to premenopausal patients. Two comparisons were planned: letrozole versus tamoxifen and letrozole+zoledronic acid versus letrozole. Primary end point was the difference in 1-year change of T-score at lumbar spine (LTS) measured by dual energy X-ray absorptiometry scan.

RESULTS

Out of 483 patients enrolled, 459 were available for primary analyses. Median age was 50 (range 28-80). The estimated mean difference (95% confidence interval [CI]) in 1-year change of LTS was equal to -0.30 (95% CI -0.44 to -0.17) in the letrozole versus tamoxifen comparison (P<0.0001) and to +0.60 (95% CI +0.46 to +0.77) in the letrozole+zoledronic acid versus letrozole comparison (P<0.0001). Bone damage by letrozole decreased with increasing baseline body mass index in premenopausal, but not postmenopausal, patients (interaction test P=0.004 and 0.47, respectively).

CONCLUSIONS

In the HOBOE (HOrmonal BOne Effects) trial, the positive effect of zoledronic acid on BMD largely counteracts damage produced by letrozole as compared with tamoxifen. Letrozole effect is lower among overweight/obese premenopausal patients.